The Tao of Excellence’s Post

Making life-saving #medicine accessible: PVR's role    We need to work harder on developing new #treatments. Here’s why:    - 6 in 10 adults in the U.S. combat a chronic condition;  - cancer cases are expected to reach almost 30 mln by 2024.    At PVR, we aim to help as many people as we can and ensure that life-saving medicines reach them.     Here’s how we make it happen:    - Accelerating trials: we cut down the time from research to treatment, ensuring that new medicines reach the market faster;  - Enhancing collaboration: by teaming up with researchers, healthcare providers, and patients, we ensure that clinical trials are relevant and medicines are distributed effectively;  - Promoting transparency: we provide clear and timely information, so patients and healthcare workers can make the best decisions related to health.    If you seek a reliable partner to help you drive your #clinicaltrial, our #PVR team is here to help.     Drop a comment below this post, and our experts will contact you with tailored advice based on your research needs.

New Research Highlights the value of syndromic PCR testing for Vaginitis! At HealthTrackRx, we’re committed to advancing diagnostic solutions that improve patient outcomes while lowering healthcare costs. A recent study, co-authored by members of our team including Azia Lavrenyuk, PhD, Steve Goldberg, MD, MBA, Maren Fragala, PhD, CSCS.D, and Jay Reddy shows that syndromic multiplex RT-PCR testing with next-day results significantly reduces follow-up outpatient services and total healthcare costs compared to alternative PCR methods or no testing at all 6 months after diagnosis. This research demonstrates how rapid and accurate molecular diagnostics empower clinicians to deliver more targeted treatments, improving patient care while reducing the financial burden of unnecessary follow-ups. Read the full summary at the link below! https://bit.ly/40gP6Kt HealthTrackRx remains dedicated to driving innovation in diagnostics to benefit both patients and healthcare providers. #HealthTrackRx #Diagnostics #MolecularTesting #HealthcareInnovation #GettingPeopleHealthierFaster

🚨📢 Publication Alert! 📢🚨 Our latest research explores innovative biomarkers for distinguishing between benign and malignant breast masses, aiding in early diagnosis and treatment decisions. 🩺🔍 Our study highlights the potential of triglyceride-glycemic index (TyG) and platelet-lymphocyte ratio (PLR) as adjunctive markers, offering cost-effective and accessible solutions for clinicians. 📈💉 Combining TyG and PLR significantly enhances predictive power, paving the way for improved patient care. 🌟🔬 These markers were chosen for their cost-effectiveness and practicality, making them invaluable in peripheral healthcare settings. 🏥💰Plus, they can aid in prioritizing referral services for patients with breast masses, potentially saving lives through early detection. 🩺✨ #BreastCancer #EarlyDetection #MedicalResearch #TyGIndex #PLR #HealthcareInnovation #ClinicalDecisionMaking 🩺💖 Read more at https://lnkd.in/gRaB42ga

In an exclusive interview, Bengt Winblad, MD, PhD, Karolinska Institutet, provides valuable insight into how society needs to be made ready for #Alzheimersdisease-modifying therapies 🎥 🧠 💡 Click here to watch 👉 https://ow.ly/Sv5W50TIy0I He highlights that improved early #diagnosis methods could lead to an influx of patients, and the importance of #doctors following treatment guidelines. Prof. Winblad acknowledges that #GPs and #memoryclinics will both be under pressure As well optimizing access to #diagnosis, payment models will need to be established given the costs associated with treatment and the high number of #MRIs needed to assess patients on the new anti-#amyloid therapies 🔦 #Alzheimers #Alz #Neurologynews #VJDementia

Two weeks ago, we asked what was on your professional development reading list for the new year. The responses were less than overwhelming, so the team at Modus Outcomes thought we'd recommend a few of our latest publications based on work with our client-collaborators. These publications showcase the kind of work we’re passionate about —focusing on what really matters to patients and making sure their voices are heard: 1. "A Patient-Relevant Measurement Strategy to Assess Clinical Benefit of Novel Therapies for Non-metastatic Cutaneous Squamous Cell Carcinoma" (https://lnkd.in/evQpYkGF) 2. "Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study" (https://lnkd.in/dPhzib8G) 3. "Patient Experience of Living With Hemophilia A: A Conceptual Model of Humanistic and Symptomatic Experience in Adolescents, Adults, and Children" (https://lnkd.in/egGarJ9h) Interested in learning more about how we can support your patient-centered outcomes research and digital health needs? Reach out to Qammer Azim for more details. #MOmentum #PatientExperience #PatientCentered #ClinicalTrials #OutcomesResearch #Innovation

🔮 Predictive Analytics for Early Detection in Healthcare 🏥✨ Here’s how AI is enhancing early detection in healthcare: 🔹 Chronic Disease Management – Predict and manage chronic diseases like diabetes, heart disease, and hypertension before they become critical. 🔹 Cancer Detection – Spot early signs of cancer through predictive algorithms that analyze medical records, genetic data, and imaging results. 🔹 Emergency Risk Prediction – Identify patients at risk of sudden medical events (e.g., strokes or heart attacks) and intervene proactively. AI-powered predictive analytics offers better outcomes, quicker interventions, and a healthier future for patients globally. Let’s embrace the power of early detection to transform healthcare. 🌍 #PredictiveAnalytics #AIinHealthcare #EarlyDetection #HealthTech #MachineLearning #PrecisionMedicine #HealthcareInnovation #DataDrivenCare #FutureOfHealthcare #LocusITServices #HireRemoteEngineer #OffshoreDevelopmentCenter

This proof-of-concept observational study shows that dd-cfDNA, a noninvasive biomarker for rejection risk, can be used to help inform physician decisions regarding IST reduction in KTx patients, along with patient evaluation and other clinical factors. #OpenAccess tinyurl.com/45s8sr9z

In the second cluster of articles from ‘The Industry Papers’ Health Liftout, our collaborators explore how Australia’s healthcare innovation leaders are paving the way in patient safety, commercialisation, and life-saving cell therapies, setting new standards for global health. Angus Dixon highlights how the Daylight Foundation is leading the fight to make healthcare-associated infections a thing of the past in ‘The invisible enemy: Driving healthcare-related infections to zero’. In the paper ‘Solving Australia's commercialisation dilemma’, Bronwyn Le Grice, (ANDHealth) discusses how Australia has the talent and resources to lead in global health innovation.  Closing out the Health Liftout, Professor Fabienne Mackay (QIMR Berghofer Medical Research Institute) unpacks Australia’s unique opportunity to lead in life-saving cell therapies and secure our place on the global stage in ‘Unlocking a boom in ground-breaking cancer treatment’. Explore the full articles at InnovationAus or secure your hard copy here: https://hubs.la/Q02R2gHc0 #PatientSafety #InfectionControl #ZeroHAIs #Commercialisation #STEM #CellTherapy #HealthcareInnovation #MedicalResearch #CancerTreatment #FutureOfHealth #IAPapers